Old Skie Areas ARe Gone but not Forgotten
Not just for skiers: Website preserves Vermont's "lost" ski areas as part of the state's history. New column at http://bit.ly/1qZ6rkf.
Noah Kahan

titsay
KIROKAZE

Jimmy Eat World
đ

Kiana Khansmith
Fieri Frames

Origami Around
"I'm Dorothy Gale from Kansas"
𩵠avery cochrane đŠľ

gracie abrams
ojovivo
â

shark vs the universe
hello vonnie

Cookie Run:Kingdom Official!
2025 on Tumblr: Trends That Defined the Year

seen from Netherlands
seen from TĂźrkiye
seen from United States

seen from United States
seen from Argentina

seen from Malaysia
seen from Israel

seen from TĂźrkiye
seen from United States

seen from TĂźrkiye
seen from United States
seen from TĂźrkiye
seen from United Arab Emirates
seen from Iraq

seen from Australia

seen from India

seen from Malaysia

seen from TĂźrkiye
seen from United States
seen from Italy
@gregdennisvt-blog
Old Skie Areas ARe Gone but not Forgotten
Not just for skiers: Website preserves Vermont's "lost" ski areas as part of the state's history. New column at http://bit.ly/1qZ6rkf.

Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch ⢠No registration required ⢠HD streaming
Novel 3-D Marker Is âGame Changerâ for Post-Surgical Radiation Therapy
When most of the business news is about big companies, itâs easy to forget that thereâs still room for a little guy with a great idea. Medical device maker Focal Therapeutics is clearly one of the latter, as a new scientific presentation underlines. The presentation was given at the 2014 Breast Cancer Coordinated Care (BC3) conference, held in February in Washington D.C.
Focal Therapeutics developed the BioZorb⢠three-dimensional surgical marker, to help identify the surgical excision site following soft tissue removal, such as breast lumpectomy cavities. The marker makes it possible for physicians to visualize the surgical region post-surgery. This helps to improve clinical precision for post-operative treatments and follow-up.
To understand the difference this makes, consider a woman who has just had a lumpectomy and now needs post-surgical radiation to prevent her cancer from returning. Once this 3D marker is placed by her surgeon, her radiation oncologist can locate the exact site more precisely, clinicians can better target the radiation (thereby decreasing the volume of tissue that receives radiation minimizing radiation exposure to nearby healthy areas such as the heart and lungs.
The presentation showed BioZorb as an alternative to traditional tissue landmarks such as seroma and clips as well as post-operative density changes seen on CT scans done for treatment planning. The results were dramatic. The device enabled physicians to achieve a greater-than-50% percent reduction in planned treatment volume, according to poster co-author Robert R. Kuske, Jr., M.D. Dr. Kuske is an internationally known radiation oncologist who uses BioZorb in his medical practice at Arizona Breast Cancer Specialists.
Whatâs more, there appeared to be no downside to using the BioZorb marker. Patients tolerated placement of the device without complications, and cosmetic outcomes were excellent.
With traditional methods, treatment planners have to do a certain amount of guesswork and treat a bigger area because the borders of the area needing treatment arenât obvious. That can mean a higher radiation dose, more risk to healthy tissue and organs, and negative impacts on the patientâs appearance.
Co-author Linda Smith, M.D. of Comprehensive Breast Care in Albuquerque, N.M. said âIt was a revelation to see the surgical edges so clearly with the BioZorb device in place.â Read more about the presentation here.
Dr. Gail Lebovic
BioZorbâs inventors appear to be true visionaries, because thereâs no other device like theirs in the medical marketplace. Unlike other markers, BioZorb defines the treatment area in three dimensions. Its unique open spiral is made of a bioabsorbable material, which means the patientâs body absorbs it slowly over time. That makes surgical removal after completion of therapy unnecessary.
Dowling & Dennis has worked with Focal Therapeuticsâ George Hermann, president and CEO, Gail Lebovic, M.A., M.D., FACS, the companyâs chief medical officer, as they have created several innovative devices in breasthealth. From all appearances, BioZorb is extending their career-long hot streak.
To Test or Not to Test? Three questions about the new PSA guidelines
A report published in Annals of Internal Medicine by the United States Preventive Services Task Force contained the following recommendation:Â healthy men do not need an annual Prostate specific antigen blood test (PSA test). The recommendation is based on evidence that suggests these test do more harm than good as they often result in men undergoing aggressive and often unnecessary treatments.
However, many physicians, including the American Urological Association, arenât happy with the new guidelines. Weâve asked Kellogg Parsons, MD, associate professor of Surgery at UC San Diego Moores Cancer Center and urologic cancer expert, three questions about the PSA test and what these new guidelines mean for menâs health.
Question:Â How does a PSA test determine whether or not a man has prostate cancer?
Answer: PSA stands for âprostate-specific antigen.â It is a blood test that acts as an early warning system for prostate cancer. It can indicate that a man has prostate cancer years before symptoms develop. This is an important concept because, by the time a man develops symptoms, it is often too late to completely cure the cancer.
Q: The article mentions that only men âexhibiting symptomsâ should be screened. What are symptoms of prostate cancer that men should be aware of?
A: Symptoms of prostate cancer are very non-specific. A good resource is the American Urological Association web site. More importantly, men should talk to their doctors about any concerns they may have.
Q: Men are notorious for skipping regular health checkups. By altering the PSA guidelines, do you think the new guidelines will do more harm than good?
A: Many, if not most, prostate cancer experts agree that these new guidelines will do more harm than good. PSA is not a perfect test. It can be abnormal in men who do not have cancer. However, if used in a responsible way, PSA screening can significantly reduce a manâs chances of dying from prostate cancer, especially in men younger than 65 years of age. Over 30,000 men die each year of prostate cancer in the U.S. Men should talk to their doctor about what PSA testing can and cannot do for them as individuals.
Photo from the American Urological Association
JAMA Breast Cancer Study Was Inaccurate
Breast cancer MD society says JAMA study was inaccurate, and wrong to criticize brachytherapy/APBI. Perspective from American Society of Breast Disease on new controversy at http://bit.ly/J1bs2G.
Breast Cancer: Favorable study on SAVI treatment
Breast cancer researchers report favorable results for a form of APBI (breast brachytherapy) called SAVI. Scientific poster at American Society of Breast Disease annual meeting: http://bit.ly/HR08Ji.

Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch ⢠No registration required ⢠HD streaming
Patients Want Online Access to Radiology Reports
From Journal of the American College of Radiology:
Most patients want online access to their radiology test results â even if the findings are difficult to understand and their doctor might not be available to discuss them right away.
Thatâs according to a study published this week in the Journal of the American College of Radiology. Researchers at Wake Forest Baptist Medical Center presented 53 adult imaging center patients with three simulated scenarios designed to determine if, and how quickly, patients want online access to radiology test results.
More in the Diagnostic imaging report at http://bit.ly/HjIr6N.